RecruitingNCT06768528

Association Between GalectiN-3 and POSt-operative AtrIal Fibrillation After Coronary Artery BypaSs Graft

Association Between Galectin-3 and Post-operative AtrIal Fibrillation After Coronary Artery Bypass Graft


Sponsor

University of Sao Paulo General Hospital

Enrollment

90 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question\[s\] it aims to answer are: * Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation? * Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Patients undergoing coronary artery bypass graft surgery

Exclusion Criteria6

  • Inability to sign the free and informed consent form
  • Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy
  • Moderate to severe left ventricular dysfunction (ejection fraction \< 40%)
  • Patients with previous atrial fibrillation
  • Pregnancy
  • Concomitant valve surgery

Interventions

DIAGNOSTIC_TESTGalectin-3 dosage

Peripheral blood sample will be collected in the 24h before CABG


Locations(1)

Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo

São Paulo, São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06768528


Related Trials